Sugi Predict

Sugi Predict / Compounds / SCHEMBL3215364

SCHEMBL3215364

SCHEMBL3215364

Cc1ccc(NC(=O)Nc2ccc(F)c(CN3CCN(C(=O)O)CC3)c2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNQ3 O43525 1/20 0.45
▸ KCNQ2 O43526 1/20 0.45
▸ ACKR3 P25106 3/20 0.45
▸ MTNR1B P49286 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KCNJ6 P48051 1/20 0.40
▸ KCNJ5 P48544 1/20 0.40
▸ KCNJ3 P48549 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ GPR6 P46095 1/20 0.40
▸ RET P07949 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ DDX3X O00571 1/20 0.40
▸ POLB P06746 3/20 0.39
▸ RORC P51449 1/20 0.39
▸ DHODH Q02127 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401596 0.90 MTNR1B (0.45) KCNQ3KCNQ2ACKR3MTNR1BNPSR1
SCHEMBL3200744 0.90 MEN1 (0.45) ACKR3NPSR1ALDH1A1NPC1RAB9A
SCHEMBL3210260 0.89 RORC (0.44) KCNQ3KCNQ2MTNR1BNPSR1ALDH1A1
SCHEMBL3206500 0.88 NPSR1 (0.48) ACKR3NPSR1ALDH1A1NPC1RAB9A
SCHEMBL3190635 0.87 NPSR1 (0.43) KCNQ3KCNQ2NPSR1ALDH1A1NPC1
SCHEMBL3209060 0.87 NPSR1 (0.43) KCNQ3KCNQ2NPSR1ALDH1A1NPC1
SCHEMBL3196401 0.86 NPSR1 (0.43) KCNQ3KCNQ2NPSR1ALDH1A1NPC1
SCHEMBL402285 0.86 ACKR3 (0.43) KCNQ3KCNQ2ACKR3NPSR1ALDH1A1
SCHEMBL3198716 0.86 MEN1 (0.55) ALDH1A1NPC1RAB9ASMN1; SMN2GPR6
SCHEMBL3204614 0.85 FAAH (0.45) KCNQ3KCNQ2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-9150564-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2015-10-06 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 KCNQ3 3753/4885KCNQ2 3396/4885ACKR3 4761/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 KCNQ3 3060/4885KCNQ2 2435/4885ACKR3 4779/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 KCNQ3 3612/4885KCNQ2 3389/4885ACKR3 4522/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 KCNQ3 3060/4885KCNQ2 2435/4885ACKR3 4779/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 KCNQ3 4642/4885KCNQ2 4428/4885ACKR3 4172/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 KCNQ3 3060/4885KCNQ2 2435/4885ACKR3 4779/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885ACKR3 4807/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 KCNQ3 4642/4885KCNQ2 4428/4885ACKR3 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.